Skip to Main Content

Brendan Frey, the founder and chief executive of Deep Genomics, thinks the wrong people are developing new drugs to treat genetic diseases. In fact, he doesn’t think humans should be doing most of the work.

It’s Frey’s view that the next wave of medicines will be discovered using artificial intelligence, and he has support from big investors to create a company that could do that: Deep Genomics on Wednesday announced a $180 million funding round led by Softbank Vision Fund 2, with participation from Fidelity Management & Research Company and others, bringing its total venture haul to $240 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment